Recruiting OBSERVATIONAL NCT06292117

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke (ORCA-AIS)

Sponsor: American Heart Association

Conditions CYP2C19 Polymorphism Ischemic Stroke

Updated 4 times since 2024 Last updated: May 1, 2024 Started: Apr 16, 2024 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on CYP2C19 Polymorphism and Ischemic Stroke, this trial is actively recruiting participants. The trial is conducted by American Heart Association and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2024 — Jul 2024 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Apr 2024 — Jun 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Heart Association
University of Virginia

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States